KEYTRUDA plus Padcev improves survival for bladder cancer patients
OXFORD - Oxford Biomedica PLC (LSE:OXB), a cell and gene therapy contract development and manufacturing organization, announced today that shareholders approved all proposed resolutions at its Annual General Meeting held in Oxford.
The company confirmed board changes that were previously announced on April 9, with Stuart Henderson stepping down from the Board of Directors effective immediately following the meeting’s conclusion. Colin Bond, who joined as an Independent (LON:IOG) Non-Executive Director in January, will succeed Henderson as Audit Committee Chair, while Peter Soelkner will assume the position of Vice Chair.
Among the approved resolutions were the adoption of the company’s 2024 annual report and accounts, the appointment of PricewaterhouseCoopers LLP as auditors, and authorizations for directors to allot shares and disapply pre-emption rights under certain circumstances.
The company reported that all resolutions were decided by poll vote, with most receiving over 99% approval from voting shareholders. The resolution regarding the Directors’ Remuneration Report received the lowest approval rate at 91.65%, with 8.35% voting against.
As of the record date of June 9, Oxford Biomedica had 106,127,365 ordinary shares in issue, each carrying one vote. The total votes cast represented approximately 73.6% of the company’s issued share capital.
The information in this article is based on a press release statement from Oxford Biomedica.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.